PRINCETON, N.J., June 13 /PRNewswire-FirstCall/ -- Novo Nordisk product previously reported as stolen in North Carolina has resurfaced recently at a medical center in Houston.
Three lots of 10 ml vials of insulin, marketed under the brand name Levemir(R) (insulin detemir [rDNA origin] injection), were taken in the original theft and identifiable by the following lot numbers: XZF0036, XZF0037, XZF0038.
A vial or vials of stolen insulin from lot XZF0037 was discovered this week at a medical center in the Houston area. Insulin from these lots did not circulate through the normal Novo Nordisk distribution channel and therefore proper storage conditions for the insulin may not have been followed.
Patients can locate the lot number on the side of the box of insulin or the side of the vial. If a patient finds their insulin is from one of the stolen lots, they should not use the insulin and contact Novo Nordisk Customer Care Center at 1-800-727-6500 for further information and instructions.
The safety of our patients is of paramount concern and we are working with our partners, the pharmacy, the FDA and law enforcement authorities to investigate the situation and take immediate steps to maintain the highest standard of safety and quality for our products.
About Levemir(R) (insulin detemir [rDNA origin] injection)
Levemir(R) is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.
Important safety information
Levemir(R) is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.
Hypoglycemia is the most common adverse effect of all insulin therapies, includin
|SOURCE Novo Nordisk|
Copyright©2009 PR Newswire.
All rights reserved